Phase 1 trial of CUDC-907, a novel, oral dual inhibitor of HDAC and Pi3k: Updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma Meeting Abstract
| Authors: | Younes, A.; Berdeja, J.; Patel, M.; Kelly, K.; Flinn, I.; Gerecitano, J.; Neelapu, S.; Copeland, A.; Wang, J.; Gong, L.; Clancy, M.; Ma, A.; Sun, K.; Wang, J.; Viner, J.; Oki, Y. |
| Abstract Title: | Phase 1 trial of CUDC-907, a novel, oral dual inhibitor of HDAC and Pi3k: Updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma |
| Meeting Title: | 21st Congress of the European Hematology Association (EHA) |
| Journal Title: | Haematologica |
| Volume: | 101 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Jun 9-12 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2016-06-01 |
| Start Page: | 175 |
| Language: | English |
| ACCESSION: | WOS:000379484600386 |
| PROVIDER: | wos |
| PMCID: | PMC4894295 |
| Notes: | Meeting Abstract: S480 -- Source: Wos |
MSK Authors
-
153Gerecitano -
319Younes -
25Copeland
Related MSK Work